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The anti-malarial artesunate also exerts profound anti-cancer activity. The susceptibility of tumor cells to artesunate can be
enhanced by ferrous iron. The transferrin receptor (TfR) is involved in iron uptake by internalization of transferrin and is over-
expressed in rapidly growing tumors. The ATP-binding cassette (ABC) transporters ABCB6 and ABCB7 are also involved in iron
homeostasis. To investigate whether these proteins play a role for sensitivity towards artesunate, Oncotest’s 36 cell line panel
was treated with artesunate or artesunate plus iron(II) glycine sulfate (FerrosanolH). The majority of cell lines showed increased
inhibition rates, for the combination of artesunate plus iron(II) glycine sulfate compared to artesunate alone. However, in 11
out of the 36 cell lines the combination treatment was not superior. Cell lines with high TfR expression significantly correlated
with high degrees of modulation indicating that high TfR expressing tumor cells would be more efficiently inhibited by this
combination treatment than low TfR expressing ones. Furthermore, we found a significant relationship between cellular
response to artesunate and TfR expression in 55 cell lines of the National Cancer Institute (NCI), USA. A significant correlation
was also found for ABCB6, but not for ABCB7 in the NCI panel. Artesunate treatment of human CCRF-CEM leukemia and MCF7
breast cancer cells induced ABCB6 expression but repressed ABCB7 expression. Finally, artesunate inhibited proliferation and
differentiation of mouse erythroleukemia (MEL) cells. Down-regulation of ABCB6 by antisense oligonucleotides inhibited
differentiation of MEL cells indicating that artesunate and ABCB6 may cooperate. In conclusion, our results indicate that
ferrous iron improves the activity of artesunate in some but not all tumor cell lines. Several factors involved in iron
homeostasis such as TfR and ABCB6 may contribute to this effect.
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INTRODUCTION
Artemisinin is a sesquiterpene isolated from Artemisia annua L.,
which is used in traditional Chinese medicine for the treatment of
fever and chills [1]. Artemisinin reveals profound activity against
Plasmodium falciparum and Plasmodium vivax [2,3]. Artesunate and
artemether are semi-synthetic derivatives of artemisinin with
improved pharmacological features [4]. In addition to their anti-
malarial activity, artemisinin and its derivatives are also active
against cancer cells [5–9]. In both cases, the activity of the drugs is
associated with the presence of iron. Iron is present in large excess
bound to hemoglobin in erythrocytes, where the Plasmodia
parasites are located. The active moiety of artemisinin-like drugs
is an endoperoxide bridge, whose reductive homolysis is promoted
by iron(II)-heme leading to C4-centered alkylating radicals [10].
These radical molecules cause macromolecular damage by
alkylating essential malarial proteins inducing cell death of
parasites [11–13]. On the other hand, iron content is higher in
tumor cells than in normal cells [14] making them more
susceptible to artemisinins. We and others have shown that the
susceptibility of tumor cells to artemisinins can further be
enhanced by the addition of transferrin or ferrous iron [15,16].
The role of artemisinins and iron for malaria treatment has
been intensively investigated during the past years [17], whereas
the role of iron for tumor treatment with artemisinins is far less
understood. The iron-binding protein, transferrin, is internalized
into cancer cells after binding to the transferrin receptor (TfR,
CD71). This is a transmembrane glycoprotein involved in iron
uptake by internalization of transferrin. TfR exerts growth
regulatory functions and is over-expressed in rapidly growing
tumors [18]. The expression of TfR is of prognostic significance
for several tumor types [19–21]. Ferrous iron can either be bound
to transferrin or to other proteins before uptake.
The ATP-binding cassette (ABC) transporters ABCB6 and
ABCB7 are involved in iron homeostasis. They are located in the
mitochondria and transport heme and protoporphyrins into these
organelles [22]. Most ABC transporters are involved in the active
transport of phospholipids, ions, peptides, steroids, polysaccha-
rides, amino acids, bile acids, pharmaceutical drugs and other
xenobiotic compounds [23].
In humans, 49 different ABC transporters have been identified,
which are classified into seven sub-families (A–G) [24]. In healthy
organs several ABC transporters protect against the harmful effects
Academic Editor: Mikhail Blagosklonny, Ordway Research Institute, United States
of America
Received May 18, 2007; Accepted July 30, 2007; Published August 29, 2007
Copyright:  2007 Kelter et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This work was funded by intramural grants.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: t.efferth@dkfz.de
. These authors contributed equally to this work.
PLoS ONE | www.plosone.org 1 August 2007 | Issue 8 | e798of xenobiotics taken up with food. A high expression can,
therefore, be found in the gastrointestinal tract, liver, and kidney.
A protective function is also given as components of the blood
brain barrier and the blood placenta barrier.
ABC transporters have been intensively investigated in the past
years. ABCB1 (P-glycoprotein, MDR1), ABCC1-C6 (MRP1-6) and
ABCG2 (BCRP) confer resistance to cytostatic drugs of tumors
and contribute to the failure of tumor chemotherapy [25]. The
mutated gene product of ABCC7 (CFTR) is involved in the
pathogenesis cystic fibrosis, and some other mutated ABC
transporter genes contribute to a number of hereditary diseases
and disorders [24]. The pathogenic function of the majority of
ABC transporters still awaits elucidation. To gain insight into
functional aspects, we have developed a low density microarray for
ABC transporters [26,27]. Applying this microarray, we identified
ABCA2 and ABCA3 as further genes involved in tumor drug
resistance [28,29].
In the present investigation, we focused on TfR, ABCB6, and
ABCB7. The aim of the present study was to address the question,
whether these proteins are involved in the response of tumor cells
to artesunate.
MATERIALS AND METHODS
Drugs
Artesunate was obtained from Saokim Ltd. (Hanoi, Vietnam) and
iron(II) glycine sulfate (FerrosanolH) from Sanol (Munich,Germany).
Cell Lines
CCRF-CEM were cultured in RPMI medium and MCF-7 and
MEL cells in DMEM medium each supplemented with 10% fetal
calf serum under standard conditions (37uC, 5% CO2). Cells were
passaged twice weekly.
Twenty-four cell lines out of Oncotest’s 36 cell line panel were
established at Oncotest from patient-derived tumor xenografts
passaged subcutaneously in nude mice [30]. The origin of the
donor xenografts have been previously described [31]. The cell
lines T24, Panc1 and 22RV1 were obtained from ATCC
(Rockville, MD, USA), the cell line LnCAP from DSMZ
(Braunschweig, Germany) and the other 8 cell lines were kindly
provided by the National Cancer Institute (Bethesda, MA, USA).
Thecultivationof55celllines(leukemia,melanoma,non-smallcell
lungcancer,coloncancer,renalcancer,ovariancancer,braintumors,
prostate cancer, and breast cancer) of the Developmental Therapeu-
tics Program of the NCI has been previously described [32].
Effect on cell growth
MEL cells were cultured with and without 1.0 mg/ml artesunate
(2.6 mM) for 24 and 48 h. Cell numbers were determined by
trypan blue exclusion.
Effect on differentiation
MEL cells (1610
6 cells/ml) were cultures in the presence of 2%
DMSO with or without 1.0 mg/ml artesunate (2.6 mM) for 28h.
The content of heme was estimated by the conversion of heme to
protoporphyrin with oxalic acid [33 Taketani et al., 2003].
Sulforhodamine B assay
Drug sensitivity of the NCI cell lines has been determined by the
sulforhodamine B assay [34 Rubinstein et al., 1990]. The 50%
inhibition concentration (IC50) values for artesunate have been
reported[7]andthoseofotheranti-cancerdrugshavebeendeposited
in the database of the NCI database (http://dtp.nci.nih.gov).
Propidium iodide (PI) assay
A modified propidium iodide assay [35] was used to assess the
compound’s activity in Oncotest’s 36 cell line panel. Briefly, cells
were harvested from exponential phase cultures by trypsinization,
counted and plated in 96 well flat-bottomed micro-titer plates at
a cell density depending on the cell line (4.000–10.000 cells/well).
After a 24 h recovery period to allow the cells to adhere and
resume exponential growth, 10 ml of culture medium (six control
wells/plate) or of culture medium containing the test compounds
were added to the cells. The compounds were applied in triplicates
at five concentrations. Following four days of continuous drug
exposure, medium or medium with test compound, including all
dead cells suspended in the culture medium, was aspirated and
replaced by 200 ml of an aqueous propidium iodide (PI) solution
(7 mg/ml). To measure the amount of living cells, cells were
permeabilized by freezing the plates, resulting in the death of all
cells that had remained attached to the bottom of the well after the
incubation period. After thawing of the plates, fluorescence was
measured using the Cytofluor 4000 micro-plate reader (excitation
530 nm, emission 620 nm), providing a direct relationship to the
total viable cell number.
Cell line array
Arrays of cell lines from the Oncotest Human Cell Line Collection
were assembled using a tissue arrayer (Beecher Instruments, Sun
Prairie, Wisc., USA) as recently described [36]. Pellet biopsies
(0.6 mm in diameter) were taken from embedded cells and arrayed
in duplicate in a new recipient paraffin block. Four-micrometer
sections of the resulting microarray block were cut and transferred
onto glass slides using the paraffin-sectioning aid system
(Instrumedics, Hackensack, NJ, USA) and further processed for
immunohistochemical staining. The arrays were stained with the
primary antibody 71C03 against TfR (Neomarkers, Fremont, CA,
USA). Staining was analyzed by light microscopy and semi-
quantitatively evaluated as described [36].
Quantitative real-time PCR
Quantitative PCR was done as described [37]. The ABI Prism
7700 Sequence Detector and Pre-Developed Assay Reagents
(Applied Biosystems, Weiterstadt, Germany) were used for the
quantification of all genes. The expression of the ABC transporters
was standardized for the expression of two housekeeping genes, b-
2-microglobulin (B2M) and Abelson gene 1 (ABL1). The ABI
Prism 7700 Sequence Detector and Pre-Developed Assay
Reagents (Applied Biosystems, Weiterstadt, Germany) were used
for the quantification of all genes. The assay IDs were: B2M:
Hs00187842_m1; ABL1: Hs00245445_m1; ABCB6:
Hs00180568_m1 and ABCB7: Hs00188776_m1.
Western blotting
MEL cells (1610
6 cells/ml) were cultured in the presence of 2%
DMSO. After 24, 48, 72, or 96 h the cells were collected and
lysed. The cellular proteins were analyzed by SDS-PAGE and
transferred onto PVDF membranes. Immunoblotting was per-
formed with antibodies for ABCB6, ABCB7, and actin as the
primary antibodies [33].
Transfection of oligonucleotides
Phosphorothioate sense and antisense oligonucleotides corre-
sponding to the mouse ABCB6 gene were transfected using
DOTAP transfection reagent (Roche Molecular Biochemicals,
Mannheim, Germany) as described [33]
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Fisher’s exact test was used to calculate significance values as
a measure for the dependency of two variables. This test was
implemented into the WinSTAT Program (Kalmia, Cambridge,
MA, U.S.A.). The TfR expression in the Oncotest panel of tumor
cell lines has been determined by a tissue micro-array technique
adapted for the examination of cell line and immunohistochem-
istry [36]. The results have been validated by conventional
immunohistochemistry and Western blotting [36]. The mRNA
expression values for TFR (clone M11507, GC102405) determined
by microarray analysis [38,39] were selected from the NCI
database (http://dtp.nci.nih.gov). The microarray-based expres-
sion levels of ABCB6 and ABCB7 have been validated by RT-PCR
[40].
RESULTS
Transferrin Receptor (TfR)
To investigate the role of TfR and iron for cellular sensitivity to
artesunate, Oncotest’s 36 cell line panel was used. The 50%
inhibition concentrations (IC50) for artesunate are shown in
Table 1. The IC50 values varied between 0.197 and
47.779 mg/ml (0.512 and 124.295 mM respectively). The mean
IC50 value was 2.791 mg/ml (7.261 mM). Furthermore, we tested
a combination of artesunate and iron(II) glycine sulfate (10 mg/ml;
FerrosanolH)( Table 1). Here, the mean IC50 value was 0.978 mg/
ml (2.544 mM) with a range from 0.013 and 22.96 mg/ml (0.026
and 59.748 mM, respectively). The data in Table 1 are arranged
according to the IC50 values for artesunate. In the majority of cell
lines, the combination of artesunate plus iron(II) glycine sulfate
resulted increased inhibition rates. However, in 11 out of the 36
cell lines (31%; OVXF 1619L, CNXF, 498NL, MCF7, RXF
393NL, MEXF 514L, MEXF 394NL, LXFL 529L, H460,
22RV1, RXF1781L, OVXL 899L) the combination treatment
was not superior to treatment with artesunate alone (degree of
modulation ,1.2). Furthermore, degrees of modulation (IC50 for
artesunate divided by the IC50 for artesunate plus iron(II) glycine
sulfate) did not correlate with IC50 values for artesunate, e.g. cell
lines with high IC50 values for artesunate were not more
modulated by the addition of iron(II) glycine sulfate than cell
lines with low IC50 values for artesunate (Table 1).
Then, we correlated the expression of TfR with the degrees of
modulation. We found that cell lines with high TfR expression
significantly correlated with high degrees of modulation (Table 2)
indicating that high TfR expressing tumor cells could be more
efficiently inhibited by a combination of artesunate and iron(II)
glycine sulfate than low TfR expressing ones. TfR expression did
not correlate with IC50 values for artesunate alone or artesunate
plus iron(II) glycine sulfate.
Furthermore, we investigated the association of TFR for
sensitivity or resistance to artesunate in 55 cell lines of the NCI
drug screening panel. We found a significant relationship between
cellular response to artesunate and TFR expression (Table 3)
indicating that TFR might be a determinant of artesunate
sensitivity in tumor cells.
ABCB6 and ABCB7
Since ABCB6 and ABCB7 are involved in iron homeostasis of
cells, we investigated a role of these two proteins for cellular
response to artesunate. Again, we used the IC50 values for
artesunate of 55 NCI cell lines. These data were correlated with
the microarray-based expression of ABCB6 (clone AF070598,
GC56272) and ABCB7 (clone AA056272, GC10226). As shown in
Table 3, a significant correlation was found for ABCB6, but not
for ABCB7.
Then, MCF-7 breast cancer cells and CCRF-CEM leukemia
cells were incubated with artesunate in a range of 0.05 to 50 mg/
ml (0.13 to 130 mM respectively) for 24 h. Afterwards, mRNA was
isolated and the expression of ABCB6 and ABCB7 determined by
real time PCR. As can be seen in Figure 1 the expression of
ABCB6 increased with increasing doses of artesunate, while the
expression of ABCB7 decreased accordingly. The induction of
gene expression by artesunate might indicate a role of these two
genes for cellular response to artesunate treatment. This can,
however, not be taken as evidence, that the two genes are
causatively related to artesunate response, and an epiphenomenal
association can not be excluded.
Finally, we treated MEL cells with artesunate (1 mg/ml,
2.6 mM). Mouse erythroleukemia (MEL) cells were used as model
to study the role of ABCB6 and ABCB7 during cellular
differentiation. While cell growth was almost stopped, only 20%
of cells died (Figure 2A). Treatment of MEL cells with 2%
DMSO leads to erythroid differentiation and heme production
(33). DMSO also induced the expression of ABCB6 and ABCB7
proteins (Figure 2B). Furthermore, the addition of artesunate
completely blocked DMSO-induced erythroid differentiation in
MEL cells in a dose-dependent manner (Figure 2B). Under these
conditions most cells were alive. This indicates that artesunate is
a potent inhibitor of proliferation and differentiation in MEL cells.
Artesunate induced protein expression of both ABCB6 and
ABCB7 (Figure 2C).
The IC50 value regarding heme production for artesunate in
MEL cells was 0.18 mg/ml (0.468 mM). We previously reported
that an antisense oligonucleotide directed against ABCB6 de-
pressed the erythroid differentiation of MEL cells to 75% [33].
When MEL cells were transfected with this antisense oligonucle-
otide and treated with artesunate (0.18 mg/ml, 0.468 mM) in
combination, the heme content decreased to about 30% control
(Figure 2D). This indicates an additive effect.
DISCUSSION
The aim of the present study was to explore the role of proteins
related to iron homeostasis for response of tumor cells to
artesunate. For this purpose, we focused on TfR and the ABC
transporters, ABCB6 and ABCB7.
We observed a wide heterogeneity of tumor cell lines towards
artesunate. Whereas iron(II) glycine sulfate was able to increase
sensitivity of tumor cells to artesunate in most cell lines, there was
no correlation between the IC50 values and high degrees of
modulation by iron(II) glycine sulfate. This indicates that iron(II)
glycine sulfate is not a typical resistance modulator comparable to
modulators of multidrug resistance, where modulating agents
completely or partially overcome resistance of a drug-resistant sub-
line to a cytostatic drug towards the level of a parental drug-
sensitive cell line [25].
It is important to point out that several cell lines did not show
increased inhibition by the combination of artesunate and iron(II)
glycine sulfate compared to artesunate alone. Some of these cell
lines did even reveal decreased efficacy to artesunate under co-
treatment with iron(II) glycine sulfate. Iron is an important
regulator of cell growth and tumor cells may take advantage of
external iron supply to grow faster. Iron(II) glycine sulfate is an
approved drug, FerrosanolH applied for many years in the clinic to
treat iron deficiency. Therefore, iron(II) glycine sulfate seems to be
a safe and suitable adjunct for combination treatments with
artesunate at first sight. Our results do, however, indicate that
there may be patients, who would not profit from addition of
Iron and Drug Resistance
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iron(II) glycine sulfate is a double edged sword improving
treatment response in the majority of tumor cell lines but
worsening it in others. Other iron preparations have also been
reported to improve the response of tumor cells to artemisinins,
e.g. ferrous sulfate or iron-loaded transferring (holotransferrin)
[9,15]. It remains to be analyzed, whether the same is true for
these iron preparations.
The fact that in some cases iron(II) gylcine sulfate could also
lead to reduced response of tumor cells towards artesunate opens
an option for the testing of tumors before treatment in a clinical
setting. If predictive tests, e.g., determination of TfR expression or
sensitivity testing by MTT assay, indicate enhanced sensitivity,
Table 1. TfR expression and in vitro anti-tumor activity of artesunate alone and in combination with iron(II) glycine sulfate
(FerrosanolH,1 0mg/ml) in Oncotest’s 36 cell line panel.
..................................................................................................................................................
Tumor Type Cell Line ART IC50 (mM) ART+Ferrosanol IC50 (mM) Degree of Modulation TfR* Cell Microarray
Ovarian Ca OVXF 1619L 0.512 0.747 0.69
Gastric Ca GXF 251L 0.578 0.193 3 0
Breast Ca MAXF 401NL 0.752 0.536 1.4 0
Ovarian Ca OVCAR3 1.168 0.871 1.34 0.33
Brain tumor CNXF 498NL 1.233 1.514 0.81
Lung Ca LXFL 1121L 1.233 0.166 7.41
Colon Ca HT29 1.381 1.061 1.3 0
Head & neck tumor HNXF 536L 1.566 0.026 60.2
Breast Ca MCF7 1.683 29.672 0.06 1
Pancreas Ca PANC1 1.733 1.017 1.7
Renal Ca RXF 393NL 1.831 5.315 0.34 0
Endometrium Ca UXF 1138L 2.125 1.272 1.67 0.33
Melanoma MEXF 514L 2.177 2.448 0.89 0
Melanoma MEXF 394NL 2.979 3.468 0.86
Melanoma MEXF 520L 4.121 0.502 8.21
Bladder Ca T24 4.519 1.332 3.39
Prostate Ca PC3M 5.341 0.341 15.67 3
Renal Ca RXF 944L 6.532 1.08 6.05 1.33
Lung Ca LXFA 526L 10.356 5.702 1.82 0
Brain tumor SF268 11.181 0.034 330.62
Melanoma MEXF 462NL 12.503 0.674 18.56 0
Prostate Ca DU145 12.503 4.188 2.99 0
Lung Ca LXFL 529L 22.31 35.609 0.63 0
Prostate Ca LNCAP 22.458 0.476 47.17 1.2
Lung Ca H460 23.809 51.465 0.46 0.5
Pleura tumor PXF 1752L 26.015 8.226 3.16
Prostate Ca 22RV1 27.412 35.362 0.78
Lung Ca LXFA 629L 27.596 15.767 1.75 0
Bladder Ca BXF 1218L 28.244 0.601 47
Colon Ca HCT116 31.054 18.351 1.69
Renal Ca RXF 1781L 41.228 36.589 1.13
Ovarian Ca OVXL 899L 46.785 58.988 0.79 0.33
Renal Ca RXF 486L 53.293 2.747 19.4 1.33
Lung Ca LXFA 289L 69.787 53.421 1.31 0
Melanoma MEXF 276L 71.748 4.121 17.41 0.33
Pancreas Ca PAXF 1657L 124.295 59.748 2.08
*TfR expression by a cell micro-array technique has been described [36].
doi:10.1371/journal.pone.0000798.t001
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Table 2. Relationship between transferrin receptor (TfR)
protein expression and degree of modulation to
a combination therapy of artesunate plus iron(II) glycine
sulfate (see Table I) in tumor cell lines of the Oncotest panel.
......................................................................
Protein Cut-off Degree of Modulation Fisher’s
#3 . 3 Exact Test
TfR ,0.5* 14 2
$0.5 1 4 p=0.011
*Relative expression. For details see [36].
doi:10.1371/journal.pone.0000798.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Iron and Drug Resistance
PLoS ONE | www.plosone.org 4 August 2007 | Issue 8 | e798a combination therapy of artesunate and iron(II) glycine sulfate
could be applied. If this is not the case, iron(II) glycine sulfate
could be skipped, and artesunate could be applied alone. This
situation adds to the attractiveness of individualized tumor
therapy. The main idea of this concept is to adapt treatment
protocols of each individual patient according to the results of pre-
therapeutic testing of efficacy of a planned therapy [41].
On the other hand, three out of the five melanoma cell lines
were clearly above-average sensitive to artesunate (individual
IC50,4.2 mM), and both more resistant melanomas
(IC50.12 mM) were strongly sensitized (degree of modulation
.15) by the addition of iron(II) glycine sulfate indicating that this
entity is especially suited for this treatment regimen. Interestingly,
these results are supported by recent clinical data. Artesunate has
been applied to two patients with otherwise drug-resistant and
refractory uveal mealoma [42]. The prognosis of refractory uveal
melanoma patients is generally worse (3–5 months). One artesu-
nate treated patient with uveal melanoma had a stable disease
following artesunate treated, but finally the tumor progressed and
the patient died after 24 months. The second patients with uveal
melanoma was treated with artesunate plus iron(II) glycine sulfate
and is still living after more than 50 months [42]. This may be
taken as a clue that the combination of artesunate plus
iron(II)glycine sulfate is indeed especially suited for this tumor
type. Further analyses have to prove this hypothesis.
Interestingly, the expression of TFR correlated with IC50 values
for artesunate alone in the panel of 55 NCI cell lines, but not in the
panel of 36 Oncotest cell lines. This is a clue that TFR expression
is only one determinant of response of tumor cells towards
artesunate. While endogenous iron might contribute to artesunate
sensitivity, exogenous iron application during artesunate treatment
is favorable for those tumors with high TFR expression levels.
In addition to TfR, iron is transported in cells by ABCB6 and
ABCB7. Therefore, we also investigated the role of these two
proteins for treatment of tumor cells with artesunate. ABCB6 is
involved in the biosynthesis of heme via interaction with
ferrochelatase, which is regulated by iron [33]. We found that
the microarray-based mRNA expression of ABCB6 but not of
ABCB7 correlated with IC50 values for artesunate in the NCI cell
line panel. While ABCB6 was induced upon artesunate treatment
in MCF7 and CCRF-CEM cells, ABCB7 expression was down-
regulated. These results speak at least in the case of ABCB6 for
a role in determining sensitivity to artesunate.
In addition to the anti-proliferative activity of artesunate on
tumor cells, we also analyzed its effect on differentiation. For this
reason, we used MEL cells, which are an established model to
study ABCB6 and ABCB7 during cellular differentiation [43].
DMSO induced both differentiation and up-regulation of ABCB6
and ABCB7 protein expression. Artesunate was able to reverse
DMSO-induced differentiation was measured by cellular heme
production. Down-regulation of ABCB6 by transfection with
antisense oligonucleotides inhibited DMSO-induced heme bio-
synthesis indicating that this protein might play a role in
differentiation.
The role of ABCB6 and ABCB7 for drug resistance has been
sparsely investigated as of yet. Boonstra et al. [44] did not find that
ABCB6 expression in small lung cancer cells was associated with
resistance to mitoxantrone. Thirteen different ABC transporters
including ABCB6 and different anti-apoptotic Bcl2 gene family
members were reported to be amplified in various drug-resistant
cell lines [45]. While the other factors may contribute to clinical
response towards neo-adjuvant chemotherapy, the specific role of
ABCB6 remains unanswered in this study. Park et al. [46]
analyzed the ABC transporter gene expression profiles in breast
cancer patients who underwent neo-adjuvant chemotherapy.
Table 3. Relationship between transferrin receptor (TFR),
ABCB6, and ABCB7 mRNA expression and response to
artesunate (ART) in tumor cell lines of the NCI drug screening
panel.
......................................................................
Gene Cut-off Artesunate Fisher’s
sensitive* resistant Exact Test
TFR ,36.15** 9 17
.36.15 19 10 p=0.022
ABCB6 ,28.05 18 9
.28.05 10 18 p=0.021
ABCB7 ,20.0482 13 14
.20.0482 15 13 not significant
*The median log10IC50 value for artesunate was used as a cut-off to separate
tumor cell lines as being ‘‘sensitive’’ or ‘‘resistant’’
**Relative mRNA expression as reported (http://dtp.nci.nih.gov)
doi:10.1371/journal.pone.0000798.t003
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Figure 1. Expression of ABCB6 and ABCB7 in MCF7 (A.) and CCRF-CEM
cells (B.) after treatment with artesunate. The expression after 24 hours
is given in relation to the expression before treatment.
doi:10.1371/journal.pone.0000798.g001
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PLoS ONE | www.plosone.org 5 August 2007 | Issue 8 | e798Figure 2. Effect of artesunate on MEL cell proliferation, differentiation, and ABCB6/ABCB7 expression. A. Effect on cell growth. MEL cells were
cultured without or with 1.0 mg/ml artesunate for the indicated time. The cell numbers were measured by trypan blue exclusion. B. Protein
expression of ABCB6 and ABCB7 after treatment with 2% DMSO for different time points. Actin expression served as loading control. C. Effect on
differentiation. MEL cells (100,000 cells/ml) were cultured in the presence of various concentrations of artesunate for 48 h. The content of heme was
estimated, by the method with oxalic acid. D. The cells transfected with sense- or antisense oligonucleotides for ABCB6 were induced with 2% DMSO
without or with 0.18 mg/ml artesunate for 48 h.
doi:10.1371/journal.pone.0000798.g002
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PLoS ONE | www.plosone.org 6 August 2007 | Issue 8 | e798Several ABC transporters including ABCB6 showed significantly
increase expression in residual disease. Again, the role of ABCB6
remains elusive. An association between ABCB7 and drug
resistance has not been reported yet.
In conclusion, our results indicate that ferrous iron improves the
activity of artesunate in some but not all tumor cell lines. Several
factors involved in iron homeostasis such as TfR and ABCB6 may
contribute to this effect. It remains to be analyzed, whether other
factors of iron metabolism (ferrochelatase, ferritin etc) are also
relevant for response of tumor cells towards artesunate
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